Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Caffeinol has been proposed as a neuroprotectant for human trials. This review covers a variety of animal models used and various attempts to take animal protocols to human trials. The accompanying paper discusses the rabbit model that was used to identify the efficacy of tissue plasminogen activator (tPA) treatment. To date, this is the only model that was able to achieve laboratory to clinical translational success. Use of caffeinol as a cytoprotective agent in rat models yielded exciting results, which led to clinical trials. However, caffeinol given with tPA in rabbits leads to increased hemorrhage. Caffeinol alone does not prove to be neuroprotective, as vasodilation by itself is not efficacious. However, vasodilation combined with thrombolysis (caffeinol with tPA) poses an increased risk of hemorrhage. For a more translational approach to study neuroprotection and neuroprotective agents in human trials, it is necessary to demonstrate the efficacy of the procedure and purported agents in several animal models.

Original publication

DOI

10.1016/j.expneurol.2004.05.008

Type

Journal article

Journal

Exp Neurol

Publication Date

08/2004

Volume

188

Pages

200 - 204

Keywords

Animals, Brain Ischemia, Caffeine, Cerebral Hemorrhage, Disease Models, Animal, Drug Therapy, Combination, Ethanol, Fibrinolytic Agents, Humans, Ischemic Attack, Transient, Neuroprotective Agents, Stroke, Tissue Plasminogen Activator